Fundraising FoxCasdin Capital — 2020 Investments
7 investments dated 2020 · listed companies and verified rows first · show all
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Chief Executive Officer, President, and Co-Founder)inDavid Schaffer(Director)inTheresa Janke(Chief of Staff, Co-Founder)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesHercules Capital, Inc.Pappas Capital+8 more
EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.
Alexis Borisy(Founder)
Co-investorsAndreessen HorowitzArboretum VenturesARCH Venture PartnersGV (Google Ventures)Nextech InvestBain Capital+1 more
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(Founder)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in
BoardRobert Nelsen(Director)Vijay Pande(Director)in
Co-investorsAndreessen HorowitzARCH Venture PartnersDeviation CapitalForesite CapitalGV (Google Ventures)HOF Capital+9 more
Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification.
BiotechDeep TechNew MaterialsSan Diego, US
J. William Efcavitch, Ph.D.(Treasurer and Chief Scientific Officer)Michael J. Kamdar(President, Chief Executive Officer and Secretary)Bill Efcavitch(Founder)Curt Becker(Founder)
BoardDavid Hwang(Director)Larry Stambaugh(Chairman of the Board of Directors)
Co-investors11.2 CapitalDCVC (Data Collective)iSelect FundKeshif VenturesRising TideAlexandria+2 more
Co-investorsLifeforce CapitalCanaan Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.